Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)

Next Previous
X
Search
Trial Profile

Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Cyclophosphamide
  • Indications Interstitial lung diseases
  • Focus Therapeutic Use
  • Acronyms SLSII; The Scleroderma Lung Study II

    • Most Recent Events

    • 08 Dec 2021 Results from Scleroderma Lung Studies (SLS) I and II evaluated the safety and efficacy of cyclophosphamide (SLS I and II) and mycophenolate (SLS II) for the treatment of SSc-ILD published in the Chest
    • 30 Dec 2020 New trial record
    • 12 Dec 2020 Results of a biomarker study using serum samples from this trial assessing predictive significance for longitudinal forced vital capacity percentage of six interferon inducible proteins (IP-10, MIG, MCP-2, B2M, TNFR2, and MIP-3 beta) published in the Arthritis and Rheumatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top